Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8094)	4/1/2003 2:17:08 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 52153

<This outbreak is extremely worrying> ...cases leapt from nearly 500 to 1,323 this week largely because Chinese health authorities officially increased their count --The infection rate may be very low compared to typical common colds. And if it depends on the presence of a second virus--that has to hamstring it. Maybe it'll peak in a month, then fade away as we head into nortern hemisphere summer. Or maybe the thing mutates and attenuates. fwiw...mortality rates for the 1918 flu pandemic were very high--at 2.5%, and up to five percent in India.

To: Biomaven who wrote (8094)	4/1/2003 2:19:26 PM
From: Biomaven	Respond to of 52153

<SARS> The NEJM medicine has some free online articles about the first cases: nejm.org One of the articles suggested that steroids/ribavirin seemed to have some immediate effect in terms of reducing fever. But there really haven't been enough cases for this to be more than a hint of efficacy. There's been some discussion of RNA on the Biotech Short thread. ICN apparently claims it (not its sub RNA) has the rights to the inhaled ribavirin - still quite unclear whether that would actually be the preferred form though, assuming it works at all, that is. Peter